Osteocyte-Derived Signaling Molecules in Skeletal Remodeling

Abstract

Osteocytes, the most abundant cells in bone, play a central role in skeletal remodeling through the secretion of a diverse array of signaling molecules. These mediators are pivotal regulators of bone homeostasis, influencing both bone resorption and formation. Recent research has illuminated the complex mechanistic pathways by which osteocyte-derived signals such as sclerostin, RANKL, FGF23, and DMP1 coordinate the activity of osteoblasts and osteoclasts. This review provides a comprehensive summary of the epidemiological relevance, pathophysiological mechanisms, risk factors, clinical features, diagnostic approaches, management strategies, recent advances, and guideline-based recommendations pertaining to osteocyte-driven skeletal remodeling, with an emphasis on translational and clinically actionable insights.

Introduction

The maintenance of skeletal integrity is an ongoing process, dynamically regulated by the interplay between bone formation and resorption. Osteocytes, terminally differentiated cells embedded within mineralized bone matrix, have emerged as key orchestrators in this process. Historically considered to be passive bystanders, osteocytes are now recognized as active regulators of skeletal remodeling via their ability to sense mechanical strain and secrete signaling molecules that modulate the activity of osteoblasts and osteoclasts. Understanding the role of osteocyte-derived factors in bone turnover is essential for clinicians involved in the management of metabolic bone diseases, such as osteoporosis and osteomalacia, as well as for the development of novel therapeutic interventions.

Epidemiology / Disease Burden

Bone remodeling dysregulation underlies a spectrum of prevalent disorders, most notably osteoporosis, which affects over 200 million individuals worldwide and is a leading cause of morbidity and mortality due to fracture risk. Osteocyte dysfunction and altered signaling are implicated in the pathogenesis of not only osteoporosis but also chronic kidney disease-mineral and bone disorder (CKD-MBD), Paget’s disease, and rare genetic skeletal disorders. The global burden of skeletal diseases is expected to rise with aging populations, underscoring the need for improved mechanistic understanding and targeted therapies.

Pathophysiology

Osteocytes communicate with other bone cells through an extensive network of dendritic processes. Their principal signaling molecules include:

Sclerostin: Encoded by SOST, sclerostin is a potent inhibitor of the Wnt/β-catenin pathway, suppressing osteoblast differentiation and bone formation. Mechanical loading reduces sclerostin expression, facilitating bone accrual, whereas disuse or immobilization increases its production and leads to bone loss.

RANKL (Receptor Activator of Nuclear Factor-κB Ligand): Osteocyte-derived RANKL is a crucial stimulator of osteoclastogenesis, promoting bone resorption. The RANKL/OPG (osteoprotegerin) ratio is tightly controlled to maintain bone mass.

FGF23 (Fibroblast Growth Factor 23): Secreted primarily by osteocytes, FGF23 regulates phosphate homeostasis and vitamin D metabolism, linking skeletal and mineral metabolism.

DMP1 (Dentin Matrix Protein 1): DMP1 is critical in mineralization and phosphate regulation. Mutations in DMP1 are associated with hypophosphatemic rickets and impaired bone mineralization.

The dysregulation of these and other osteocyte-derived signals disturbs the balance between bone formation and resorption, leading to microarchitectural deterioration and increased fracture risk.

Risk Factors

Risk factors for altered osteocyte signaling include aging, menopause, chronic glucocorticoid use, immobilization, chronic kidney disease, and genetic mutations affecting sclerostin, DMP1, or FGF23 pathways. Lifestyle factors such as low physical activity, poor nutrition, and smoking further contribute to osteocyte dysfunction and skeletal fragility.

Clinical Features

Clinical manifestations of disrupted osteocyte signaling are primarily related to bone fragility, manifesting as low-trauma fractures, bone pain, and skeletal deformities. In genetic disorders (e.g., sclerosteosis, X-linked hypophosphatemia), features may include abnormal bone density, enthesopathy, and dentin defects. CKD-MBD patients often present with bone pain, muscle weakness, and increased fracture risk due to impaired FGF23 signaling and osteocyte dysfunction.

Diagnosis

Diagnosis relies on clinical evaluation, fracture history, and imaging (DXA, HR-pQCT) to assess bone density and microarchitecture. Biochemical markers, including serum sclerostin, FGF23, phosphate, and vitamin D levels, aid in identifying underlying signaling abnormalities. Genetic testing may be indicated for suspected hereditary disorders. Bone biopsy remains the gold standard for definitive assessment of bone turnover and mineralization defects.

Treatment & Management

Management strategies target both the underlying disease and modulation of osteocyte signaling pathways. Anti-resorptive agents (bisphosphonates, denosumab) reduce osteoclast activity, while anabolic therapies such as teriparatide and abaloparatide stimulate bone formation. Sclerostin inhibitors (romosozumab) represent a novel class that directly antagonizes osteocyte-derived sclerostin to enhance bone formation and reduce fractures. Management of secondary contributors, such as optimizing calcium and vitamin D intake, treating CKD, and encouraging weight-bearing exercise, is essential. Patient-specific risk assessment and tailored therapy are recommended for optimal outcomes.

Recent Advances / Emerging Therapies

The development of sclerostin-neutralizing antibodies (e.g., romosozumab) has revolutionized the management of osteoporosis, offering dual anabolic and anti-resorptive effects. Ongoing research into modulators of RANKL and FGF23 signaling shows promise for the treatment of rare genetic and acquired bone disorders. Gene therapy, small molecule inhibitors, and targeted monoclonal antibodies represent future directions for precision modulation of osteocyte-derived pathways. Additionally, advances in imaging and biomarker development are enhancing the ability to monitor osteocyte function and treatment response in clinical practice.

Guideline Recommendations

Current guidelines from major societies (e.g., Endocrine Society, American Society for Bone and Mineral Research) recommend the use of anti-resorptive or anabolic therapies for patients at high fracture risk, with consideration for sclerostin inhibitors in postmenopausal women with severe osteoporosis. Assessment of bone mineral density, correction of secondary causes, and individualized therapy based on risk stratification are emphasized. Regular monitoring and reassessment of treatment efficacy and safety are advised. For rare inherited disorders, referral to specialized centers for genetic counseling and advanced management is recommended.

Conclusion

Osteocyte-derived signaling molecules are critical determinants of skeletal remodeling, bone strength, and overall mineral homeostasis. Advances in our understanding of these pathways have led to transformative therapies with significant clinical impact. Continued research into osteocyte biology will pave the way for novel interventions, improved patient outcomes, and the realization of precision medicine in metabolic bone disease.